Close Menu

Brandi Davis-Dusenbery

Mar 15, 2017

Seven Bridges has promoted Brandi Davis-Dusenbery to CEO. She succeeds Co-founder Deniz Kural, who is assuming the role of executive chairman of the board of directors. Davis-Dusenbery was the former senior vice president of science and product for Seven Bridges. Prior to Seven Bridges, she worked as a fellow at Harvard University's Department of Stem Cell and Regenerative Biology.

More Like This

Aug 13, 2020

Myriad Genetics: Paul Diaz

Myriad Genetics has appointed Paul Diaz as its new president and CEO, effective Aug. 13, 2020. Diaz, who will also serve on Myriad's board of directors, will take over from Bryan Riggsbee, who has been serving as the company's interim president and CEO, and CFO after Mark Capone's resignation from that post in February. Diaz served as president, CEO, and in various other roles at Kindred Healthcare, a provider of post-acute healthcare services, for more than a decade. He was also a partner at the private equity firm Cressey & Company LP, and has served as an executive and board member at multiple public and private companies. He is currently on the board of DaVita and a member of the board of trustees of Johns Hopkins Medicine. 

Aug 07, 2020

Pacific Biosciences: Christian Henry, Michael Hunkapiller, John Milligan, Ben Gong

Pacific Biosciences has appointed Christian Henry as president and CEO effective Sept. 14, 2020. Henry has served on the board of directors since 2018, including as chairman since March 2020.

John Milligan, a board member since 2013, has been appointed to succeed Henry as chairman, also effective Sept. 14.

As previously announced, Michael Hunkapiller will retire from an active operating role at the end of the year. Effective Sept. 14, Hunkapiller will assume the position of senior fellow focused on technology development until his retirement. Hunkapiller will also continue to serve on the company's board.

In addition, Pacific Biosciences has named Ben Gong as interim CFO to succeed Susan Barnes, who's retirement from the position was previously announced.

Aug 07, 2020

Tangen Biosciences: Vance Kershner, Alan Levin

Tangen Biosciences has appointed Vance Kershner and Alan Levin to its board of directors in conjunction with a $12.2 million Series B preferred stock financing. Kershner is founder, president, and CEO of LabWare, which develops and implements software for automating laboratory operations. Levin previously served as president and CEO of drugstore chain Happy Harry's, which merged with the Walgreen Company in 2006. Levin also previously served as the Director of the Delaware Economic Development Office.

Aug 06, 2020

Crown Bioscience: John Gu

Crown Bioscience has been appointed John Gu as chief operations officer. Gu joins Crown Bio from WuXi Nextcode, where he was general manager for the China business and chief digital officer. Prior to WuXi, Gu was held successive senior technology and operations roles across digital and technology companies, including Alcatel-Lucent. 

Aug 05, 2020

Integrity Laboratories: Maria Cekanova

Integrity Laboratories has appointed Maria Cekanova CSO. She was previously director of translational research laboratory and research associate professor of oncology in the department of small animal clinical sciences at the University of Tennessee. Integrity recently received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 Assay.

Aug 04, 2020

Lexogen: Stéphane Barges, Alexander Seitz

Sequencing firm Lexogen has appointed Stéphane Barges as CEO, effective Sept. 1. 

Barges comes to Lexogen from Qiagen, where he was VP of molecular diagnostics. He has 20 years of experience in the life science and clinical diagnostics industry, including management positions at Life Technologies, Bio-Rad Laboratories, and Tecan. He holds a doctorate in genetics and molecular biology from the University of Geneva and an MBA from HEC Geneva.

Barges will succeed Lexogen founder Alexander Seitz, who will take on the role of chief innnovation officer.

Jul 31, 2020

Talis Biomedical: Roger Moody, Kim Popovits, Walter Koch

Talis Biomedical has named Roger Moody as CFO, while Kim Popovits has joined the company's board and Walter Koch has joined its scientific advisory board.

Moody was formerly CFO of Clinical Genomics. He previously was chief executive and COO at Glysure and CFO of Nanosphere and Medsn. Popovits is the former chairman of the board, president, and CEO of Genomic Health, which was acquired by Exact Sciences. She also held several management positions at Genentech, now part of Roche. Koch was at Roche Molecular Systems where he held several leadership roles, including vice president and head of global research. Prior to that, he was at the US Food and Drug Administration.

Jul 30, 2020

ACMG Foundation for Genetic and Genomic Medicine: Nasha Fitter

The ACMG Foundation for Genetic and Genomic Medicine, a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice, has elected Nasha Fitter to its board of directors. Fitter currently serves as director of Rare and Neurological Diseases at Ciitizen. She is also cofounder, CEO, and head of research at FOXG1 Research Foundation, an organization focused on finding a cure for FOXG1 syndrome. Previously, Fitter founded and served as CEO of Schoolie, and prior to that worked as director of the Global Schools Program at Microsoft Education.

Jul 29, 2020

Agendia: Brian Dow

Agendia has appointed Brian Dow as CFO. Prior to this position, he served as senior VP and CFO of Pulse Biosciences, where he was responsible for executing the company's early-stage IPO and subsequent follow-on offerings. Before that, he was CFO at Progyny, and prior to that, he was VP and principal accounting officer at Pacific Biosciences. Previously, he also worked for Ernst & Young. Dow holds a bachelor's degree from Georgia Institute of Technology.

Jul 28, 2020

Aegea Biotechnologies: George Maltzeos

Aegea Biotechnologies said that it has hired George Maltzeos as chief engineer to help expedite the development of the company's point-of-care lateral flow molecular SARS-CoV-2 test being developed in collaboration with Tauriga Sciences. Maltzeos previously served as director of the California Institute of Technology Global Health Initiative where he helped secure $4.5 million in funding from the Bill & Melinda Gates Foundation to develop point-of-care clinical diagnostics for developing countries. He also previously founded and served as chief engineer for Helixis, which was acquired by Illumina in 2010. Maltzeos holds a PhD in electrical engineering from CalTech and a BS from Columbia University.

Jul 28, 2020

Clinical Genomics: Michael Paris, Zivjena Vucetic, Edward Rosen

Clinical Genomics has appointed Michael Paris as chief operating officer, Zivjena Vucetic as senior VP, medical, and Edward Rosen as chief strategy and commercial officer.

Paris most recently served as COO and senior VP, operations and technology development, at Origin. Prior to Origin, he served in several positions at Bioconnect Systems, Orthovita, and Rex Medical. 

Before Clinical Genomics, Vucetic served as medical director at Ortho-Clinical Diagnostics. Prior to that, she held multiple scientific and medical roles at Fujirebio Diagnostics. 

Rosen most recently served as an executive in residence at Columbia University. Prior to Columbia, he held several research roles at Johnson & Johnson. 

Jul 28, 2020

Meridian Bioscience: Anthony Bihl

Meridian Bioscience announced the appointment of Anthony Bihl to its board of directors, effective immediately. Bihl retired in April as CEO of Bioventus and was previously the CEO of American Medical Systems and CEO of Siemens Medical Solutions Diagnostics. He has also served in senior executive roles at Bayer Healthcare's diagnostics division and in multiple operations and finance roles at Dupont.

Jul 27, 2020

Veracyte: Jens Holstein, James Erlinger

Veracyte has appointed Jens Holstein to its board of directors and James Erlinger as executive VP, general counsel, and secretary.

Holstein was appointed as CFO of MorphoSys in 2011. Prior to MorphoSys, he served as regional CFO of the Europe/Middle East region for Fresensius Kabi, a subsidiary of Fresenius. He has also held several other leadership roles within the Fresenius group. 

Erlinger previously served as executive VP, general counsel, and secretary of Iqvia. He spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner. 

Jul 24, 2020

SeqBiome: Marcus Claesson, Paul Cotter, Brad Wrigley

University College Cork spinout SeqBiome announced its management team this week. Marcus Claesson is the company's CEO, Paul Cotter is the firm's chief technology officer, and Brad Wrigley is executive director.

Claesson is a principal investigator at APC Microbiome Ireland. He has a PhD in bioinformatics from the National University of Ireland and an MSc in bioinformatics, as well as a BSc in chemical engineering and physics, from Chalmers University of Technology in Gothenburg, Sweden.

Cotter is head of food biosciences at Teagasc and a principal investigator with APC Microbiome Ireland, Vistamilk SFI Centres, and Food for Health Ireland. He holds PhD and BSc degrees in microbiology from University College Cork.

Wrigley has been working with several startup and spinout companies. He has more than 20 years of experience as a director, entrepreneur, investor, and CEO in government and industry, including at Accenture, Dell EMC, and Virtustream.

Jul 24, 2020

Cradle Genomics: Tanya Moreno, Sue Gross

Prenatal diagnostics firm Cradle Genomics has appointed Tanya Moreno as VP of development and Sue Gross as chief medical officer.

Moreno has 13 years of experience in diagnostics development and the commercialization of genomic tests. She holds a PhD in molecular genetics and developmental biology from the California Institute of Technology.

Gross joins the company from Sema4, where she was medical director for the reproductive lab and clinical analysis division. Previously, she was chief medical officer at Natera, and before that, professor of obstetrics and gynecology, pediatrics, and genetics at Montefiore Einstein. She is a physician with board certifications in obstetrics and gynecology as well as medical genetics.

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.